# Korea Kolmar Co.

> Korea Kolmar Co. is a VC fund in Seoul backing Biotechnology and Medical. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 13
- Last investment: Jun 2026
- Lead investor: 31%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kolmarkorea/
- Website: http://www.kolmar.co.kr/
- Facebook: https://www.facebook.com/kolmar.korea

Korea Kolmar Co. is a VC fund in Seoul focused on Biotechnology and Medical. Korea Kolmar Co. engaged in the manufacture and sale of cosmetics. The Company operates in two divisions: cosmetics and pharmaceuticals. Its cosmetics division involves in the business of original development and design manufacturing (ODM) and original equipment manufacturing (OEM) of cosmetics including skin care, makeup, hair care, body care andothers. Its pharmaceutical division involves in the development and production of pharmaceutical products and quasi-drugs including general medicines, specialized medicines, bioequivalence medicines and others.

## Contacts

5 contacts available for Korea Kolmar Co.. Shizune tracks 2 team members at Korea Kolmar Co.. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/korea-kolmar-co?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.5M–$2.2M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 31% |
| Medical | 3 | 23% |
| Beauty | 2 | 15% |
| Pharmaceutical | 2 | 15% |
| B2B | 1 | 8% |

29 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 31% |
| Series B | 2 | 15% |
| Funding Round | 2 | 15% |
| Series A | 1 | 8% |
| Series C | 1 | 8% |

7 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Choi Hak-bae | President | 0 | https://shizune.co/investors/profile/choi-hak-bae |
| Ho-Kyung Lee | CEO | 0 | https://shizune.co/investors/profile/ho-kyung-lee |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| The SMC Group | The SMC Group is a social marketing company. | $13M |  | Jun 18, 2026 |  |
| Woojung Bio | Woojung Bio is a bio infrastructure development company that constructs smart laboratories animal rooms for the purpose of research. | $23.6M | Post-IPO Debt | Mar 05, 2026 |  |
| Bistool | Bistool provides Facial silicone implant silicone prosthesis Soft Seal, including rhinoplasty prostheses, and used products in domestic cosmetic surgery clinics. | $2.2M | Seed | Jun 10, 2025 |  |
| MyIB | MyIB offers a matching gift program for businesses.MyIB commodities enterprises have a software platform called 'Give & Match' as well as a matching gift program. |  | Seed | May 30, 2024 |  |
| MyIB | MyIB offers a matching gift program for businesses.MyIB commodities enterprises have a software platform called 'Give & Match' as well as a matching gift program. |  | Seed | Apr 02, 2024 |  |
| ProEn Therapeutics | ProEn Therapeutics is a bio-drug development company that focuses on protein engineering. |  | Corporate Round | Mar 04, 2024 |  |
| Brexogen | Brexogen is a biotechnology cell therapy research and development company. | $9.1M | Series C | Sep 01, 2023 |  |
| Biome ATS | BioM ATS intends to provide the fundamental infrastructure required to progress the complex strain design platform and foster technical collaboration with microbiome firms through proof-of-concept (POC) of the complex strain design technology. It is a strategy to begin the platform business in earnest by the end of the year, with an emphasis onplatform advancement and collaboration with industry, academia, research institutes, and the military. | $1.5M | Seed | Jun 28, 2023 |  |
| Biomatz | Biomatz is a biotechnology company specializing in microbiome therapeutics. Their proprietary platform designs cooperative microbial consortia by isolating and analyzing complex gut microbiota interactions, facilitating the development of live biotherapeutic products. It aims to advance personalized medicine and gut health solutions withapplications spanning pharmaceuticals, nutraceuticals, and functional foods.​ | $1.5M | Seed | Jun 28, 2023 |  |
| Cell in Cells | Cell in Cells is a biotechnology and life sciences company. It is involved in cell therapy and regenerative medicine. The company developed Therapeutic Organoid Intelligence, a proprietary platform to harness cells' self-organizing potential to regenerate and restructure tissues without synthetic scaffolds. | $10.4M | Series B | Jul 26, 2021 |  |

10 of 13 investments shown.

## Co-investors
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 4 deals together
- [Angel Ventures](https://shizune.co/investors/profile/angel-ventures-mexico) — VC Fund, 2 deals together
- [Daewoong Pharmaceutical](https://shizune.co/investors/profile/daewoong-pharmaceutical) — VC Fund, 2 deals together
- [Gyeongnam Venture Investment](https://shizune.co/investors/profile/gyeongnam-venture-investment) — VC Fund, 2 deals together
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 2 deals together
- [Premier Partners](https://shizune.co/investors/profile/premier-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Soma Capital](https://shizune.co/investors/profile/soma-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Beauty Investors in South Korea](https://shizune.co/investors/beauty-investors-south-korea)
- [Beauty VC Funds in South Korea](https://shizune.co/investors/beauty-vc-funds-south-korea)
- [Medical Device Investors in South Korea](https://shizune.co/investors/medical-device-investors-south-korea)
- [Medical Device VC Funds in South Korea](https://shizune.co/investors/medical-device-vc-funds-south-korea)
- [B2B Investors in South Korea](https://shizune.co/investors/b2b-investors-south-korea)
- [B2B VC Funds in South Korea](https://shizune.co/investors/b2b-vc-funds-south-korea)

## FAQ

### What does Korea Kolmar Co. invest in?

Korea Kolmar Co. invests primarily in Biotechnology, Medical and Beauty startups, most often at Seed and Series B stage. Most of the 13 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Korea Kolmar Co.'s check size?

Korea Kolmar Co. typically joins rounds of $1.5M–$2.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Korea Kolmar Co. participates in.

### How do I contact Korea Kolmar Co.?

Public channels for Korea Kolmar Co. include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Korea Kolmar Co.?

The team at Korea Kolmar Co. includes Choi Hak-bae (President) and Ho-Kyung Lee (CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co